文献速递神经肿瘤

[68Ga] DOTATATE PET/MRI引导的脑膜瘤放射外科治疗计划与反应评估

[Ga68] DOTATATE PET/MRI-guided radiosurgical treatment planning and response assessment in meningiomas.
PubMed 文献 · Neuro Oncol · 2024-01-01

本研究前瞻性纳入27例脑膜瘤患者(64个肿瘤),术后行DOTATATE PET/MRI用于放射外科计划,放疗后6-12个月复查。结果显示放疗后SUV和SUVRSSS分别下降37.4%和44.4%(P<.0001),但肿瘤大小仅缩小8.9%,未达RANO标准的25%显著性阈值。DOTATATE PET/MRI可能是评估脑膜瘤放疗反应的影像生物标志物。

要点

  • 放疗后SUV和SUVRSSS分别下降37.4%和44.4%(P<.0001),而肿瘤大小仅缩小8.9%,未达RANO标准的25%阈值。
  • 中位随访26个月(范围6-44),34个月时WHO-1/2/3亚组的PFS分别为100%/100%/54%。
  • SRS队列中SUVRSSS每降低10个单位,Cox回归显示风险比为0.48。

核心结论

  • DOTATATE PET的SUV和SUVRSSS在放射外科后显著下降,肿瘤大小缩小有统计学意义但未达RANO标准的临床显著性。
  • DOTATATE PET/MRI可能是评估脑膜瘤放射外科治疗反应的有前景的影像生物标志物。

研究设计与样本

  • 前瞻性研究,27例脑膜瘤患者共64个肿瘤(26% WHO-1级,41% WHO-2级,26% WHO-3级,7% WHO-未知级)。
  • 患者术后行DOTATATE PET/MRI,PET与钆增强T1加权MRI融合用于放射外科计划。
  • 放射外科后6-12个月行随访DOTATATE PET/MRI,获取最大绝对SUV和以SSS血池为参照的SUVRSSS。
  • 肿瘤大小变化按RANO标准评估,SUVRSSS变化幅度与PFS的关联采用Cox回归分析。
  • 治疗为立体定向放射外科(SRS)或立体定向体部放疗(SBRT;平均剂量30 Gy,众数剂量35 Gy,平均5次分割)。

主要发现

  • 放疗后SUV和SUVRSSS分别下降37.4%和44.4%(P<.0001)。
  • 肿瘤大小乘积缩小8.9%,未达RANO指南确定的25%显著性阈值。
  • 平均随访26个月(范围6-44),34个月时总体平均PFS为83%,WHO-1/2/3亚组分别为100%/100%/54%。
  • 最大随访(42-44个月)时,WHO-1/2/3亚组PFS分别为100%/83%/54%。
  • Cox回归分析显示,SRS队列中SUVRSSS每降低10个单位,风险比为0.48。

关键数值与推荐

  • RANO标准规定肿瘤大小乘积变化需达到25%阈值方为显著。
  • SUV和SUVRSSS分别下降37.4%和44.4%(P<.0001)。
  • 肿瘤大小乘积缩小8.9%,未达25%阈值。
  • 34个月时总体平均PFS为83%,WHO-1/2/3亚组分别为100%/100%/54%。
  • 最大随访(42-44个月)时WHO-1/2/3亚组PFS分别为100%/83%/54%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Our purpose was to determine the utility of [68Ga]-DOTATATE PET/MRI in meningioma response assessment following radiosurgery. METHODS: Patients with meningioma prospectively underwent postoperative DOTATATE PET/MRI. Co-registered PET and gadolinium-enhanced T1-weighted MRI were employed for radiosurgery planning. Follow-up DOTATATE PET/MRI was performed at 6-12 months post-radiosurgery. Maximum absolute standardized uptake value (SUV) and SUV ratio (SUVRSSS) referencing superior sagittal sinus (SSS) blood pool were obtained. Size change was determined by Response Assessment in Neuro-Oncology (RANO) criteria. Association of SUVRSSS change magnitude and progression-free survival (PFS) was evaluated using Cox regression. RESULTS: Twenty-seven patients with 64 tumors (26% World Health Organization [WHO]-1, 41% WHO-2, 26% WHO-3, and 7% WHO-unknown) were prospectively followed post stereotactic radiosurgery (SRS) or stereotactic body radiotherapy (SBRT; mean dose: 30 Gy, modal dose 35 Gy, mean of 5 fractions). Post-irradiation SUV and SUVRSSS decreased by 37.4% and 44.4%, respectively (P < .0001). Size product decreased by 8.9%, thus failing to reach the 25% significance threshold as determined by RANO guidelines. Mean follow-up time was 26 months (range: 6-44). Overall mean PFS was 83% and 100%/100%/54% in WHO-1/-2/-3 subcohorts, respectively, at 34 months. At maximum follow-up (42-44 months), PFS was 100%/83%/54% in WHO-1/-2/-3 subcohorts, respectively. Cox regression analyses revealed a hazard ratio of 0.48 for 10-unit reduction in SUVRSSS in the SRS cohort. CONCLUSIONS: DOTATATE PET SUV and SUVRSSS demonstrated marked, significant decrease post-radiosurgery. Lesion size decrease was statistically significant; however, it was not clinically significant by RANO criteria. DOTATATE PET/MR thus represents a promising imaging biomarker for response assessment in meningiomas treated with radiosurgery. CLINICALTRIALS.GOV IDENTIFIER: NCT04081701.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Ivanidze J, Chang SJ, Haghdel A, et al. [Ga68] DOTATATE PET/MRI-guided radiosurgical treatment planning and response assessment in meningiomas. Neuro Oncol. 2024. PMID: 38553990. doi:10.1093/neuonc/noae067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。